Our study now provides evidence of a clinically relevant increase in its activity in CAP and, thus, suggests acid sphingomyelinase as a potential target for host directed treatments to reduce end-organ damage in pneumonia. This evidence concerns the gene SMPD1 and susceptibility to pneumonia measurement.